JP2022553954A5 - - Google Patents

Info

Publication number
JP2022553954A5
JP2022553954A5 JP2022523564A JP2022523564A JP2022553954A5 JP 2022553954 A5 JP2022553954 A5 JP 2022553954A5 JP 2022523564 A JP2022523564 A JP 2022523564A JP 2022523564 A JP2022523564 A JP 2022523564A JP 2022553954 A5 JP2022553954 A5 JP 2022553954A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
formula
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022523564A
Other languages
English (en)
Japanese (ja)
Other versions
JP7716396B2 (ja
JP2022553954A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/056684 external-priority patent/WO2021081108A1/en
Publication of JP2022553954A publication Critical patent/JP2022553954A/ja
Publication of JP2022553954A5 publication Critical patent/JP2022553954A5/ja
Priority to JP2025120941A priority Critical patent/JP2025157436A/ja
Application granted granted Critical
Publication of JP7716396B2 publication Critical patent/JP7716396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022523564A 2019-10-22 2020-10-21 前立腺癌を治療する方法 Active JP7716396B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120941A JP2025157436A (ja) 2019-10-22 2025-07-18 前立腺癌を治療する方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962924655P 2019-10-22 2019-10-22
US62/924,655 2019-10-22
US201962945418P 2019-12-09 2019-12-09
US62/945,418 2019-12-09
US202063028843P 2020-05-22 2020-05-22
US63/028,843 2020-05-22
US202063032453P 2020-05-29 2020-05-29
US63/032,453 2020-05-29
PCT/US2020/056684 WO2021081108A1 (en) 2019-10-22 2020-10-21 Methods of treating prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120941A Division JP2025157436A (ja) 2019-10-22 2025-07-18 前立腺癌を治療する方法

Publications (3)

Publication Number Publication Date
JP2022553954A JP2022553954A (ja) 2022-12-27
JP2022553954A5 true JP2022553954A5 (https=) 2023-10-20
JP7716396B2 JP7716396B2 (ja) 2025-07-31

Family

ID=73449188

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022523564A Active JP7716396B2 (ja) 2019-10-22 2020-10-21 前立腺癌を治療する方法
JP2025120941A Pending JP2025157436A (ja) 2019-10-22 2025-07-18 前立腺癌を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120941A Pending JP2025157436A (ja) 2019-10-22 2025-07-18 前立腺癌を治療する方法

Country Status (10)

Country Link
US (2) US20210113557A1 (https=)
EP (1) EP4048236A1 (https=)
JP (2) JP7716396B2 (https=)
KR (1) KR20220087482A (https=)
CN (1) CN115135313A (https=)
AU (1) AU2020370150A1 (https=)
CA (1) CA3158411A1 (https=)
IL (1) IL292359A (https=)
MX (1) MX2022004808A (https=)
WO (1) WO2021081108A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
WO2022048605A1 (zh) * 2020-09-04 2022-03-10 南昌奥瑞药业有限公司 一种杂环化合物、其制备方法、中间体、组合物以及应用
JP2023547084A (ja) * 2020-10-21 2023-11-09 アルビナス・オペレーションズ・インコーポレイテッド アンドロゲン受容体タンパク質の標的分解のための化合物および方法
JP2023552818A (ja) * 2020-12-11 2023-12-19 アルビナス・オペレーションズ・インコーポレイテッド 前立腺癌を治療する方法
CN113620931B (zh) * 2021-09-13 2023-06-09 中国海洋大学 一种雄激素受体抑制剂及其用途
US20250248999A1 (en) * 2022-04-21 2025-08-07 Arvinas Operations, Inc. Bavdegalutamide and combinations thereof for use in treating prostate cancer
WO2024233696A1 (en) * 2023-05-09 2024-11-14 Arvinas Operations, Inc. Bavdegalutamide for treating prostate cancer without ar l702h mutation
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
WO2015114314A1 (en) * 2014-01-28 2015-08-06 Cipla Limited Pharmaceutical composition comprising abiraterone
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
WO2016081472A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual formulation of riluzole
CN109310664A (zh) * 2016-06-10 2019-02-05 田纳西大学研究基金会 选择性雄激素受体降解剂(sard)配体和其使用方法
JOP20190067A1 (ar) * 2016-09-30 2019-03-28 Janssen Pharmaceutica Nv طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法

Similar Documents

Publication Publication Date Title
JP2022553954A5 (https=)
JP2022546471A5 (https=)
TWI800914B (zh) Fxr激動劑之固體形式
JP2025116875A5 (https=)
IL178745A (en) Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma
US12077554B2 (en) CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
KR20070014184A (ko) 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
JP2019515884A5 (https=)
JP2024520630A5 (https=)
JP2017530175A5 (https=)
JP2010540508A5 (https=)
JP2022544711A5 (https=)
US11065240B2 (en) Drug combinations to treat multiple myeloma
JP2016534063A5 (https=)
JP2020533283A5 (https=)
CN106999462A (zh) 包含选择性s1p1受体激动剂的药物组合物
JP2024531188A5 (https=)
JP2021534160A5 (https=)
EP2124930B1 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
JP2025118775A5 (https=)
JP7854206B2 (ja) 肺線維症の予防または治療用の薬学製剤
JP2022518288A5 (https=)
EP1345610B1 (en) Quetiapine for treating of dyskinesia in non-psychotic patients
JP7788550B2 (ja) ターフェニル化合物の安息香酸塩の製造方法
EP0623346A1 (en) Inhibitor for metastasis of malignant tumor